Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Empower Clinics $CBDT.ca $EPWCF Kai Medical Laboratory Achieves Record Testing Volume Month in October and Signs Numerous New Contracts $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:30 AM on Friday, November 13th, 2020

Kai Medical Laboratory, a state-of-the-art diagnostics laboratory in Dallas, was acquired by Empower Clinics on October 6, 2020 to further advance the Company’s COVID-19 national testing programs for enterprise clients, including movie and television studios, businesses and colleges

  • KAI testing volume of 1,375 units in October represents a sequential increase of 763% over testing volume in September of 180 units.
  • Moreover, the increase comes from only a partial month of control under Empower given the acquisition of KAI was only completed on October 6, 2020.
  • Finally, given the very recent closing of the acquisition, the record October results were achieved without the benefit of Empower’s planned sales, marketing and rollout plans for KAI.

VANCOUVER, BC / November 13, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) has achieved record testing volume for the month of October with 1,375 units processed.

RECORD ACHIEVED IN PARTIAL FIRST MONTH UNDER EMPOWER CLINICS

KAI testing volume of 1,375 units in October represents a sequential increase of 763% over testing volume in September of 180 units. Moreover, the increase comes from only a partial month of control under Empower given the acquisition of KAI was only completed on October 6, 2020. Finally, given the very recent closing of the acquisition, the record October results were achieved without the benefit of Empower’s planned sales, marketing and rollout plans for KAI.

Empower Clinics Chairman and CEO, Steven McAuley, stated “The magnitude of KAI’s growth and success in October cannot be overstated as an example of what is to come. This is especially true given the fact we have yet to fully implement the sales and marketing strategies planned for KAI as we expand our national testing programs for enterprise level clients across America. Though we are very pleased with the results achieved in October, the testing volume of 1,375 units represents a fraction of the lab’s capacity which is capable of achieving 4,000 COVID-19 RT-PCR tests per day. It is our intention to continue ramping up growth significantly through 2020 and well into 2021.”

GROWTH STRATEGIES & NUMEROUS NEW COMMERCIAL TESTING CONTRACTS

The Company is now working through integration and implementing aggressive growth strategies including servicing new COVID-19 testing contracts for the film & television industry, banks, restaurants, tourism and supporting the Sun Valley Health COVID-19 RT-PCR and rapid antibody testing programs in the state of Arizona.

To this end, on October 7th, Empower announced it had commenced COVID-19 RT-PCR tests for a major studio film & television production. On October 19th, Empower announced a partnership with Loop Insights to provide the first ever “travel bubble” solution for the global travel industry.

Finally, Empower has signed numerous new commercial testing contracts, the details of which will be provided in subsequent press releases.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

The combination of all this commercial activity since the October 6th acquisition provides the Company with the confidence necessary to support the expectation of much further growth in the months to come.

COVID-19 RT-PCR TESTING IS THE GOLD STANDARD THAT ALLOWS EMPOWER TO ROLL OUT NATIONAL PHASE 4 TESTING PROGRAMS

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

The Company has also granted an aggregate of 1,079,666 stock options (each, an “Option“) to certain key employees of the Company in accordance with the Company’s stock option plan priced at $0.05 CAD and 1,500,000 Options priced at $0.08 CAD to an investor relations service provider.

This press release is available on the Empower Clinics Verified Forum on AGORACOM for shareholder discussion, questions and engagement with management https://agoracom.com/ir/EmpowerClinics

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Momentum Health acquisition may not be completed on the terms expected or at all; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: , , , , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF Kai Medical Laboratory Achieves Record Testing Volume Month in October and Signs Numerous New Contracts $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

VIDEO – $KABN.ca Joins Forces With Some Of World’s Biggest Companies To Help Build The New Model For Internet-Scale Digital Trust $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 4:55 PM on Thursday, November 12th, 2020
kabn-square-new

When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.

This led to the enactment of the biggest data privacy laws in history.  Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).

Enter KABN.  The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.

More than just lip service, KABN announced joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust. As part of this community, KABN is focused on bridging the gap between traditional fintech services and solutions and new and innovative Verified Credential processes. Does that sound like a mouthful?  Yeah, it does.  But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future.  Government regulations are enforcing it.  Consumers are demanding it and KABN is delivering it at such an advanced scale that the Trust Over IP Foundation has provided them with a strategic role as a Steering Member to help drive the following mission:  

“I am certain KABN will make a strong contribution to the Trust over IP Foundation.” said John Jordan, executive director, BC Digital Trust Service and executive director of ToIP. “People and businesses are going to continue using the internet to build relationships and complete transactions digitally with all the risks of security breaches and fraud that go along with it today. It’s time for a change. Global leaders are working together at our Foundation to make it possible for people to be known and to build trusted relationships online. I am happy to have KABN be part of this effort.”

KABN was so ahead of this curve they were actually too early to the game … now the game is underway with KABN sitting in a great field position.
Watch this interview with President David Lucatch and welcome to the next potential great disruptive industry of the decade.

Tags: , , , , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, KABN, KABN Systems NA Holdings Corp. | Comments Off on VIDEO – $KABN.ca Joins Forces With Some Of World’s Biggest Companies To Help Build The New Model For Internet-Scale Digital Trust $MOS.ca $MOGO.ca $CTZ.ca

Avicanna $AVCN.ca $AVCNF Announces Overnight Marketed Public Offering of Units $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 4:38 PM on Thursday, November 12th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Announced that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta , British Columbia , Manitoba , Ontario and Saskatchewan in connection with a marketed public offering of units of the Company
  • Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant
  • Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at any time for a period of 24 months following closing of the Offering
  • Final pricing of the Units, the Warrant exercise price and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering

TORONTO , Nov. 12, 2020 – Avicanna Inc. (” Avicanna “, or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that it has filed and has been receipted for a preliminary short form prospectus with the securities commissions in Alberta , British Columbia , Manitoba , Ontario and Saskatchewan (the ” Canadian Jurisdictions “) in connection with a marketed public offering (the ” Offering “) of units (the ” Units “) of the Company.

Each Unit will consist of one common share of the Company (each a ” Common Share “) and one-half of one common share purchase warrant (each full warrant, a ” Warrant ” and collectively the ” Warrants “). Each Warrant will be exercisable for one Common Share (each a ” Warrant Share “) at any time for a period of 24 months following closing of the Offering. Final pricing of the Units, the Warrant exercise price and the determination of the number of Units to be sold pursuant to the Offering will be determined in the context of the market prior to the filing of the final short form prospectus in respect of the Offering. The Offering will be conducted on a “best efforts” basis by a syndicate of agents led by Echelon Wealth Partners Inc., as lead agent and sole-bookrunner, and including Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the ” Agents “).

The Company has granted the Agents an option, exercisable in whole or in part, at the sole discretion of the Agents, at any time for a period of 30 days from and including the closing of the Offering, to purchase from the Company up to an additional 15% of the Units sold under the Offering, on the same terms and conditions of the Offering to cover over-allotments, if any, and for market stabilization purposes (the ” Over-Allotment Option “). The Over-Allotment Option may be exercised by the Agents to purchase additional Units, Common Shares, Warrants or any combination thereof.

The Offering will be completed (i) by way of a short form prospectus to be filed in the Canadian Jurisdictions (ii) on a private placement basis to “accredited investors” meeting ‎one or more ‎of the ‎criteria in Rule 501(a) of ‎Regulation D (” Regulation D “) ‎under the United States Securities Act of 1933 , as amended (the ” U.S. Securities Act “) pursuant to Rule 506(b) ‎of Regulation D and/or ‎Section ‎‎‎4(a)(2) thereof and similar exemptions under ‎applicable state securities ‎‎laws, ‎Qualified Institutional ‎Buyers in the United States pursuant to the registration exemptions provided by Rule 144A of the US ‎Securities Act, and (iii) outside Canada and the United States on a basis which does not require the qualification or registration of any of the Company’s securities under domestic or foreign securities laws.

The Offering is expected to close on or about December 3, 2020 , or such other date as the Company and the Agents may agree. Closing of the Offering is subject to customary closing conditions, including, but not limited to, the execution of an agency agreement and the receipt of all necessary regulatory approvals, including the approval of the securities regulatory authorities and the Toronto Stock Exchange.

The Company intends to use the net proceeds of the Offering for product development, working capital and general corporate purposes.

The preliminary short form prospectus is available on SEDAR at www.sedar.com .

This news release does not constitute an offer to sell or a solicitation of an offer to sell any of securities in the United States . The securities have not been and will not be registered under the U.S. Securities Act or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About Avicanna Inc.

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development, and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W™: an advanced and clinically tested line of CBD consumer derma-cosmetic products; and,
  • RHO Phyto™: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all 2 developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its derma-cosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta , Colombia . Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020 , Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia .

Stay Connected

For more information about Avicanna, visit www.avicanna.com , call 1-647-243-5283, or contact Setu Purohit , President by email at [email protected] .

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by the Company, including expectations and assumptions regarding the terms, timing and potential completion of the Offering, satisfaction of regulatory requirements in various jurisdictions and the use of proceeds from the Offering.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of manageme nt’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, the delay or failure to receive regulatory approvals, and the risk factors set out in the Company’s annual information form dated April 15, 2020 , filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com .

SOURCE Avicanna Inc.

Tags: , , , , , , , , ,
Posted in All Recent Posts, Avicanna Inc. | Comments Off on Avicanna $AVCN.ca $AVCNF Announces Overnight Marketed Public Offering of Units $WEED.ca $TLRY $HARV.ca

6 Small Cap Stocks That Are Providing Real Products and Solutions In The Fight Against #Coronavirus #COVID19 $DM.ca $CBDT.ca $INNO.ca $KNR.ca $MTRX.ca $PRMO.ca

Posted by AGORACOM-JC at 12:18 PM on Thursday, November 12th, 2020
What do you call the disease caused by the novel coronavirus? Covid-19

The devastation and destruction of Coronavirus COVID-19 is well documented and doesn’t need much repeating here. 

What we do know is that COVID-19 has created global demand for highly specialty products required to protect, test, detect and defend as many people as possible. 

Moreover, given its persistence and the potential for a 2nd wave around the world, governments and businesses both big and small are now in need of solutions that go beyond locking down economies by helping them stay open, generate revenue, keep people employed … all while keeping them safe.

There are no magic bullets.  COVD-19 didn’t exist 12 months ago, so there are no established or incumbent leaders.  This has created an opportunity for small but nimble companies with high-tech expertise to adapt their products as solutions in one of the many verticals that require help fighting COVID-19.

Here are 6 small-cap companies (in alphabetical order) that have provided real solutions to helping the fight against COVID-19.

Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC )an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution.  When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.

REVENUE $CAD

Q1 + 62% To $809,000

Q2 + 419% To $1,954,000

TOTAL Q1 AND Q2

REVENUE     $2.8M vs $875K = +220%

GROSS PROFIT $1.2 vs $739K = +62%

Given the speed of incoming contracts, the quarterly financials don’t reflect deals done during the third quarter. Here’s just a few;

  • Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
  • Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
  • $20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020)
  • Received Third COVID-19 Order from TV Production Company (September 21, 2020)
  • Received  COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)

··      The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.

The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.

For more information, please visit the Datametrex AI hub on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for …. but that’s not all. In an effort to combat COVID-19 the company’s physician staffed clinics have are also generating significant revenue and growth as follows:  

  • Increased CBD treatments from patients suffering increased anxiety;
  • Covid-19 Testing for individuals and families
  • Covid-19 Testing for local businesses and employees 
  • Covid-19 Testing for enterprise level organizations across the country 
  • Empower Clinics and Loop Insights Combine COVID-19 Testing Expertise With Venue Tracing To Create First Ever “Travel Bubble” Solution For Global Travel Industry Set To Lose $3.3 Trillion
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 RT-PCR tests per day. RT-PCR tests are considered the gold standard of COVID-19 testing

How significant is this acquisition that only closed a couple of weeks ago? At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.

Patient Visits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth. 

For more information about the company, please check out the Empower HUB on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is an Israeli based company developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

Innocan, together with Tel Aviv University are developing new, revolutionary exosome based technology (CLX), loaded with cannabidiol (CBD) targeting the coronavirus infected lung cells.

Why is this significant?

CLX may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. It is expected to be administrated by inhalation, CLX will be tested on a variety of lung infections focusing on patients infected by the coronavirus disease.

Superior Management Team

More than just lip service, Innocan has a world class management team to make this happen.

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The Innocan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world

Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)

Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.

Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

While the Company develops their pharmaceutical solution, Innocan has a portfolio of patent-pending and launch ready consumer health products that are already commercializing around the world as follows:

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

To support this global growth, Innocan already has the following relationships in place:

Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)

Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)

Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.

As a result, Kontrol is already achieving commercial success as follows:

·         Q1 $2.3M

·         Q2 $2.7M

TOTAL Q1 AND Q2

  • REVENUE                 $5M
  • GROSS PROFIT        $2.7M

ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS

As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.

GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH

Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.

The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:

Early tests suggest new Canadian technology could detect the coronavirus in the air Read More

Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.

Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More

CSA APPROVAL RECEIVED ON NOVEMBER 5TH

On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

For more information about the company, please check out the Kontrol Energy hub on AGORACOM.

Loop Insights (MTRX:TSXV)(RACMF:OTCQB) was already a leading provider of contactless solutions and artificial intelligence (“AI”) to the brick and mortar space prior to the arrival of COVID-19.

Over the last few months Loop has adapted its contactless platform to also provide contact tracing and real-time testing to large venues and businesses.  More than just lip service, Loop has already announced significant partnerships and news with the likes of:

TELUS  

Loop was recently accepted into the TELUS IoT Marketplace for national sales and marketing to TELUS business Customers. 

Andrew Turner, TELUS VP Strategic Operations,

“By partnering with innovative and leading IoT development companies, such as Loop, we’re ensuring that our customers have access to some of the most advanced IoT business solutions in the world.” 

AMAZON 

On October 29th, the Company announced that Amazon Web Services (AWS) and Loop Insights would be hosting an interactive webinar to showcase the Company ‘ s Venue Tracing Solution to a global audience of businesses to learn about the technical, security, privacy, and commercial aspects of Loop ‘ s Venue Tracing Platform. 

The invitees were from industries including but not limited to: 

  • Airlines
  • Venue Owners
  • Sports & Entertainment
  • Telecom
  • Government

How did the webinar go?  On October 30th Loop announced Early Response To Amazon Web Services And Loop Insights Showcase Of Loop Venue Tracing Solution To Global Audience Indicates Great Success

The presentation ended at approximately 1:15 PM EST, and by 8:00 PM EST Loop had received over 100 direct inquiries from enterprise-level attendees spanning many different industries and countries. Loop Insights anticipates many more direct inquiries to be received in the coming days.

Loop Insights CEO Rob Anson:

“We knew going into the webinar that interest in our Contactless Platform and Solutions was very high given the high-level nature of clients we had already announced leading up to it. These attendees, many of whom represent household name entities, were looking to us for solutions that can protect people, instill confidence in their customers and get their enterprises moving once again. Nonetheless, the response to the demonstration of our Contactless Venue Tracing Platform was simply incredible and even surpassed our expectations. We are optimistic that Loop Insights is establishing an identity as a global force in the contactless space and believe the responses will lead to significant business for Loop. We can’t thank Amazon Web Services enough for their continued support and partnership.”

In addition to these successes, Loop stated that its Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:

  • Implemented Into the Las Vegas flagship properties of a Global Hospitality company (July 23, 2020)
  • Invited by NCAA DIV 1 BIG EAST CONFERENCE To Present Solution For 11 schools (August 17, 2020)
  • Partnership with BDG sports to deliver NBA, NHL, NCAA and PGA Sporting Events. (August 13, 2020)
  • Implemented By University Of Houston  (September 16, 2020)
  • Loop Insights Signs $1,930,000 USD License Deal with Austin, TX Based CasaPerks (September 28, 2020)
  • Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas (October 8, 2020)

For more information about the company, please check out the Loop Insights hub on AGORACOM.

Primo Nutraceuticals, a player in the hemp space pivoted early in the pandemic to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category. The company further solidified its move to PPE by entering into agreement with Duquette Consulting LLC, a company owned by Dan Duquette.

Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products.

The company has been issued a Medical Device Establishment License from Health Canada.The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing of all four classes of medical devices for human use in Canada. These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.

The PPE Distribution Market worth $28.9 Billion by 2025 in North America and E.U

The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.

For more information about the company, please check out the Primo Nutraceuticals hub on AGORACOM.

Thanks for reading and discovering these great small cap companies. Please be sure to visit the AGORACOM Small Cap Coronavirus Covid-19 company gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small_Cap_Coronavirus_Covid-19%20

Tags: , , , , , , ,
Posted in All Recent Posts, Datametrex AI Limited, Empower Clinics Inc., Featured, Innocan Pharma Corporation, Kontrol Energy Corp., Loop Insights Inc., PRIMO Nutraceuticals Inc., Small Cap Coronavirus COVID-19 Stocks | Comments Off on 6 Small Cap Stocks That Are Providing Real Products and Solutions In The Fight Against #Coronavirus #COVID19 $DM.ca $CBDT.ca $INNO.ca $KNR.ca $MTRX.ca $PRMO.ca

Primo Nutraceuticals $PRMO.ca Enters into a Binding LOI to acquire 100% of the Assets of Full Spectrum Biosciences Inc. $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 10:28 AM on Thursday, November 12th, 2020
  • Announced that it has signed a binding letter of intent (“LOI”) with Full Spectrum Biosciences Inc.(“FSB”),a Colorado company
  • FSB is an intellectual property (“IP”), formulation and white label provider that has conducted sales via e-commerce, online, Amazon and doctors’ offices within the United States offering popular CBD, CBG and Hemp oil extract products like RehabRx and Hemp Pops
  • The Company will be acquiring the assets and inventory of FSB. The LOI is legally binding and subject to the negotiation of a definitive agreement

VANCOUVER, British Columbia, Nov. 12, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) is pleased to announce that it has signed a binding letter of intent (“LOI”) with Full Spectrum Biosciences Inc.(“FSB”),a Colorado company.

FSB is an intellectual property (“IP”), formulation and white label provider that has conducted sales via e-commerce, online, Amazon and doctors’ offices within the United States offering popular CBD, CBG and Hemp oil extract products like RehabRx and Hemp Pops. The Company will be acquiring the assets and inventory of FSB. The LOI is legally binding and subject to the negotiation of a definitive agreement (the “ Definitive Agreement ”).

TERMS OF THE TRANSACTION

The Company will acquire 100% of the revenue generating assets including the web sites for the popular CBD, CBG and Hemp oil extract products like RehabRx, ( www.rehabrx.com ) and Hemp Pops, ( www.hemppops.com ), the current inventory and the sales and distribution networks that have generated approximately $25,000 to $30,000 USD in monthly revenues since 2018 (the “Transaction”). Gross margin is estimated at 30%.

The consideration for the Purchase will be stipulated in the form of a number of common shares of PRIMO (the “Consideration Shares”) at a per share price equal to the volume weighted average price of such shares on the Canadian Securities Exchange over a 15-day period ending on the day such Consideration Shares are required to be issued (“15 day VWAP”). The consideration paid by Primo to FSB for the Transaction shall be based on an independent valuation of the Assets by a Third Party Valuator. The valuation is currently in progress.

There will be no Change of Control or Fundamental change of business. The Transaction will be subject to review by the parties’ tax, corporate, and legal advisors prior to Closing. The senior management team of PRIMO will consist of those officers presently appointed by the board of directors of PRIMO and shall remain the same.

About Agritek Holdings Inc. and Full Spectrum Biosciences

FSB is a licensed Colorado Corporation which is a wholly owned subsidiary of Agritek Holdings Inc. existing under the laws of the State of Delaware as a “C” corporation, and a publicly traded company on the OTC Markets under the symbol “AGTK” (“Agritek”).

Agritek Holdings, Inc. ( www.AgritekHoldings.com ), is a fully integrated, active real estate investor and advisor of white label brands in the legal cannabis sector. Specifically, Agritek Holdings provides strategic capital and functional expertise to accelerate the commercialization of its diversified portfolio of cannabis related real estate holdings. The hemp based raw material and products produced at facilities owned by Agritek Holdings and leased back to licensed operators are then used for retail branded CBD, CBG and Hemp oil extract products produced by its subsidiary Full Spectrum Biosciences presently sold via e-commerce, online, Amazon and Doctors offices within the United States. Brands include RehabRX , Hemp Pops, MD Vapes , and multiple white labeled brands. Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act

“REHAB RX” – Pain Cream, Tinctures, and Gummies; www.rehabrx.com

“HEMP POPS” – CBD Infused Lollipops, Ice Popsicles; www.hemppops.com

Rehabrx.com and Hemppops.com are owned and operated by Full Spectrum Biosciences, Inc., a Colorado corporation with offices in Colorado.

The Global CBD Market

The global CBD market is expected to reach USD 146.4 billion by the end of 2025, according to a new report by Grand View Research, Inc. Growing adoption of marijuana in several medical applications such as cancer, mental disorders, chronic pain and others is expected to propel revenue growth in near future.

Richard Cindric , CEO Comments:

“We are extremely excited to be signing a LOI with Full Spectrum. Gaining FSB’s IP, formulation, white label resources as well as it’s already developed brands like RehabRx and Hemp Pops is a major milestone for the company. As we enter the US nutraceutical market with this acquisition, we believe FSB’s assets compliments our nutraceutical line of products very well. We look forward to working with the FSB team, as well as the introduction of possible future acquisitions.”

Michael Friedman, CEO of Full Spectrum Comments:

“I am pleased to deliver on our promise to the Agritek shareholders that our wholly owned subsidiary Full Spectrum Biosciences has entered into this asset purchase agreement with Primo Nutraceuticals. By having access to both the Canadian and US public markets through Primo, we can work to build our company in both jurisdictions and bring greater value through our combined management teams and contacts for our wellness brands. Our recently announced test pilot program with Biomedican (www.Biomedican.com) using proprietary yeast for synthetic cannabinoid profiles in my opinion will propel our combined companies to an entirely different level within the nutraceutical space and allow us to compete as a biotech within the wellness sector under our new parent company Primo Nutraceuticals”, stated B. Michael Friedman, CEO Agritek Holdings Inc.”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’smanagement is in the process of building a corporate road map to further vertically integrate the Company; specifically, by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Richard Cindric
CEO and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com

www.twitter.com/prmonutra

www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Tags: , , , , , , , , ,
Posted in PRIMO Nutraceuticals Inc. | Comments Off on Primo Nutraceuticals $PRMO.ca Enters into a Binding LOI to acquire 100% of the Assets of Full Spectrum Biosciences Inc. $MRS.ca $FTI.ca $MMM $HON $MSA

$KABN.ca Network Joins the Trust Over IP Foundation $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 9:19 AM on Thursday, November 12th, 2020
kabn-square-new
  • Announced a strategic role as a Steering Member of the Trust over IP (“ToIP”) Foundation (www.trustoverip.org).
  • In taking on this role, KABN joins other Steering Members including Accenture, Anonyme Labs, Continuum Loop, Evernym, Finicity, Futurewei, IBM, ID Ramp, LG CNS, Mastercard and others.
  • The Trust over IP Foundation has over 170 members, including organizations as well as individuals, collaborating together with the common objective of changing the way people interact online.

TORONTO, ON and GIBRALTAR / November 12, 2020 / The KABN Network together with KABN Systems NA Holdings Corp. (CSE:KABN) (the “Company” or “KABN North America“) (www.kabnsystemsna.com), a Canadian Fintech company that specializes in continuous online identity verification, management and monetization in Canada and the US, today has announced a strategic role as a Steering Member of the Trust over IP (“ToIP”) Foundation (www.trustoverip.org).

In taking on this role, KABN joins other Steering Members including Accenture, Anonyme Labs, Continuum Loop, Evernym, Finicity, Futurewei, IBM, ID Ramp, LG CNS, Mastercard and others. The Trust over IP Foundation has over 170 members, including organizations as well as individuals, collaborating together with the common objective of changing the way people interact online.

The Trust over IP Foundation is defining a complete architecture for Internet-scale digital trust that combines both cryptographic trust at the machine layer and human trust at the business, legal, and social layers. As part of this community, the KABN Network is focused on bridging the gap between traditional fintech services and solutions and new and innovative Verified Credential processes.

KABN aims to use proven bank-grade identity verification processes to allow Holders (who use a credential), Verifiers (who confirm the validity of a credential) and Issuers (who produce the credential) to complete transactions of many kinds including financial services, eCommerce transactions, organization, building and visitor access badges among others.

“I am certain KABN will make a strong contribution to the Trust over IP Foundation.” said John Jordan, executive director, BC Digital Trust Service and executive director of ToIP. “People and businesses are going to continue using the internet to build relationships and complete transactions digitally with all the risks of security breaches and fraud that go along with it today. It’s time for a change. Global leaders are working together at our Foundation to make it possible for people to be known and to build trusted relationships online. I am happy to have KABN be part of this effort.”

Businesses today struggle to protect and manage digital assets and data, especially in an increasingly complex enterprise environment that includes the Internet of Things (IoT), Edge Computing, Artificial Intelligence and much more. This is compounding the already low consumer confidence in the use of personal data and is slowing innovation on opportunities like digital identity and the adoption of new services that can support humanity.

The KABN Network believes that without a global standard for how to ensure digital trust, these struggles are bound to continue. The four layers of Trust over IP’s dual governance and technology stack establish a clear model for how utilities, technical components, business rules and human-focused design can combine to solve this set of problems. The digital trust ecosystems that emerge from Trust over IP will help businesses, citizens and governments alike use the internet to create enduring trusted relationships that allow transactions to be completed safely and with confidence.

“With the ToIP Technology and Governance Stack, the industry is now in a position for an Identity Paradigm shift. Future generations will have a hard time believing that there was a day when everyone was anonymous on the Internet and we believe that the KABN Network is at the forefront of this evolution,” said RJ Reiser, KABN North America CBDO, Director and Co-Chair ToIP Ecosystem Foundry Working Group.

About the Trust over IP Foundation

Launched in 2020, the Trust over IP Foundation is an independent project hosted by the Linux Foundation. Its members include over 150 leading companies, organizations and individual contributors sharing expertise and collaborating to define standard specifications to advance a secure trust layer for the digital world. Through this collaborative effort, the Trust over IP Foundation aims to define a complete architecture for Internet-scale digital trust that combines cryptographic trust at the machine layer with human trust at the business, legal, and social layers. For more information, please visit us at trustoverip.org.

The Linux Foundation has registered trademarks and uses trademarks. For a list of trademarks of The Linux Foundation, please see its trademark usage page: www.linuxfoundation.org/trademark-usage. Linux is a registered trademark of Linus Torvalds.

About KABN North America – www.kabnnaholdco.com

KABN Systems NA Holdings Corp. through its wholly owned subsidiary KABN Systems North America Inc. focuses on the verification, management and monetization of digital identity, empowering users to control and benefit from its use of their online identity. KABN proprietary technology suite includes 4 key products:

Liquid Avatar allows users to create high quality digital icons representing their online personas. These icons, in conjunction with KABN ID, allow users to manage and control their Digital Identity and to use Liquid Avatars to share public and permission based private data when they want and with whom they want. www.liquidavatar.com

KABN ID is an Always On, biometric and blockchain based digital identity validation and verification platform allowing users to continuously and confidently prove themselves throughout the online community.

KABN Card is a Visa approved prepaid card program allowing users to manage both digital and fiat currencies and earn cashback and other loyalty incentives. www.kabncard.com

KABN KASH is a cashback, loyalty and engagement program that powers the KABN revenue ecosystem.

KABN provides its products and services at no cost to consumers and generates revenues through permission-based partner programs. www.kabnkash.com

For more information, please visit www.kabnnaholdco.com or www.kabnsystemsna.com

For further information, please contact:

David Lucatch
Chief Executive Officer
647-725-7742 Ext. 701
[email protected]

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the KABN Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, information concerning the ability of the Company to generate revenues, roll out new programs and to successfully achieve business objectives, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE: KABN Systems NA Holdings Corp.

Tags: , , , , , , , , ,
Posted in Featured, KABN, KABN Systems NA Holdings Corp. | Comments Off on $KABN.ca Network Joins the Trust Over IP Foundation $MOS.ca $MOGO.ca $CTZ.ca

Avicanna $AVCN.ca $AVCNF Reports Third Quarter 2020 Financial Results and Provides Corporate Update $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 9:05 AM on Thursday, November 12th, 2020
http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

  • Another double-digit increase in revenue quarter over quarter as the company continues to execute on its business plan to commercialize its brands in different geographic markets and product segments.
  • Successful launch of the RHO Phyto line of advanced medical cannabis products nationwide in Canada in partnership with Medical Cannabis by Shoppers Drug Mart Inc.
  • Good Preparation Practices certification and authorization by the National Institute for Drug and Food Surveillance (“INVIMA”) for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia.

TORONTO, Nov. 12, 2020 –Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the third quarter ended September 30, 2020.

Aras Azadian, Chief Executive Officer of Avicanna, commented “We are thrilled to report the tremendous progress our team continues to make in our commercialization and research efforts. During the third quarter, we were able to demonstrate the superiority of our technologies and products with several strategic commercial partnerships but also with an incredibly successful launch of our medical products in the Canadian market.”

Third Quarter Highlights

  • The Company continued to make strides in its strategic commercial initiatives, leading to an increase in revenue of approximately 24% from Q2-2020, continuing the trend of double-digit growth, quarter over quarter from Q4-2019. In addition, the Company was able to reach a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams. Below is a summary of the revenue trend over the last four quarters.
  • Avicanna launched the first product of its RHO Phyto branded line of medical cannabis products on the Medical Cannabis by Shoppers™ (“Shoppers”) platform on August 12, 2020. As of the date of this MD&A, Avicanna has launched its oil drops and sublingual sprays, for a total of four SKUs, through the Shoppers online platform, which offers nationwide service to Canadians.

  • Certain of the RHO Phyto products are participating in the Medical Cannabis Real-World Evidence study (“MC-RWE study”) at the University Health Network (“UHN”). This first-of-its-kind Canadian study is led by Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital, and will examine the efficacy of a select group of medical cannabis products including Avicanna’s RHO Phyto line of products on patient reported outcomes of pain, sleep and anxiety. This specific study is aligned and in parallel with Avicanna’s comprehensive clinical program of other real-world evidence studies involving the RHO Phyto products and clinical trials on its pharmaceutical pipeline with world-class, Toronto-based medical institutions.

  • The Company hosted its third annual symposium, “Medical Cannabis 2.0”, through a virtual format on July 21, 2020. The presentations focused on the evolution of medical cannabis including the Avicanna led advancements in R&D for novel cannabinoid delivery forms and formulations. Presenters including Dr. Ruth Ross (Professor and Chair, Department of Pharmacology & Toxicology, Faculty of Medicine, University of Toronto, Senior Scientist, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health) and Dr. Hance Clarke (Staff Anesthesiologist, Director Pain Services, Director Good Hope Ehlers Danlos Clinic, Medical Director of The Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Associate Professor, Department of Anesthesia, University of Toronto). Over 1,000 participants attended the symposium.

  • The Company announced on September 14, 2020 that through Avicanna LATAM S.A.S., the Company’s pharmacy in Bogota has been certified with Good Preparation Practices and authorized by INVIMA for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia. This is the final step in the Company’s fully integrated seed to patient business model in Colombia, which includes cultivation, extraction and manufacturing of pharmaceutical products for the emerging medical market of 50 million people.

  • Avicanna announced on July 24, 2020 that its research collaborators had received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (“NSERC”). In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation. Avicanna further expanded its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC grant to investigate the neural basis of cannabis-induced toxicosis. The NSERC grants are being used to expand the investigators’ collaborative research with Avicanna at little to no additional cost to the Company.

  • Avicanna and Red White & Bloom Brands Inc. (“RWB”) entered into a distribution agreement (the “Distribution Agreement”) on August 11, 2020, for the exclusive distribution of Avicanna’s hemp-based CBD derma-cosmetic and topical products, branded as Pura H&W™, by RWB in the United States and certain other markets. Under the Distribution Agreement, which has an initial five-year term, RWB will exclusively distribute the Pura H&W™ brand and certain other white label brands at RWB’s direction. In exchange for this exclusivity, RWB is required to pay Avicanna an upfront exclusivity fee in the amount of CAD$250,000 in cash, along with minimum purchase requirements for the rights to be the exclusive distributor of Avicanna’s Pura H&W branded cosmetic products in the US. Under the Distribution Agreement, RWB also has the right to purchase Avicanna’s cosmetic products for distribution into the United States and certain other territories under brands of RWB’s choosing. The initial product offerings under the Distribution Agreement includes body and face lotions, cosmetic creams, gels and serums, as well as soaps and bath bombs.

  • The Company issued an aggregate of 1,952,410 units (the “August Units”) at a price of $1.40 per August Unit, for aggregate gross proceeds of approximately $2.7 million on August 18, 2020. Each August Unit was comprised of one Common Share and one-half of one Common Share purchase warrant, each whole warrant exercisable into one Common Share at a price of $2.00 per share until August 18, 2022, subject to acceleration rights.

  • The Company announced on August 24, 2020 that it completed exports of CBG and CBD isolates into the USA and CBD isolate into Germany. The Company also commenced a pilot tracking system for the export of its active pharmaceutical ingredient products in partnership with TruTrace Technologies Inc.

  • The Company announced on September 4, 2020 that it completed further exports of CBD water soluble formula into the USA and CBD-based cosmetics into the United Kingdom. The Colombian Ministry of Health also granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.

  • The Company announced that it entered into an agreement with a US distributor partner on September 29, 2020, whereby the Company plans to develop certain hemp-derived cannabinoid-based products, including sublingual and sustained release tablets intended for the sleep market for such US distributor. Under the agreement, the Company is developing the intellectual property that forms the basis of the products for a development fee. The Company will receive an ongoing royalty payment based on the gross revenue of the products, and the Company will have the opportunity to supply cannabinoid for the manufacture of the products.

  • During the quarter, the Company incurred general and administrative (G&A”) expenses that total $2,954,438. While the Company’s G&A expenses did marginally increase from the previous quarter, there were several expenses incurred that were one time in nature. Below is a summary of the adjusted EBITDA of the Company over the last four quarters, indicating its continued improvement.
 Q1 2020Q2 2020Q3 2020
Revenue260,903709,468881,956
Adjusted EBITDA*(3,063,524)(3,641,496)(2,608,063)
 
* Adjusted EBITDA is a Non-GAAP measure. Please refer below for a reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA.
  • Subsequent to quarter end, on November 2, 2020, the Company closed a non-brokered convertible debenture financing, pursuant to which it issued convertible debentures (the “Debentures”) with an aggregate Face Principal Amount (as defined below) of $1,100,000 (the “Debenture Financing”). The Debentures bear interest at 8.0% per annum and will mature on the date that is 12 months from the ‎date of issuance, with the first year of interest payable in advance on the date of ‎issuance and capitalized and added into the principal amount (such aggregate amount being, ‎the “Face Principal Amount”). With these funds the Company was able to strengthen its balance sheet and provide the necessary working capital to make a large commercial push in the first quarter of 2021.

Summary of Operations ($CDN)

 Three Months EndedNine Months Ended
 September 30,
2020		September 30,
2019		September 30,
2020		September 30,
2019
     
   $$
Revenues881,9564,9431,852,32745,537
Impairment on inventory(612,105)–(612,105)–
Inventory Production Costs expensed to Cost of Sales(439,099)–(673,387)–
Fair value changes in biological assets included in inventory sold(37,818)–(607,370)–
Unrealized gain/(loss) on changes in fair value of biological assets(1,103,910)–723,361–
General and administrative2,954,4385,673,5409,064,84312,604,022
Share-based compensation839,954262,4982,455,9161,982,066
Depreciation and amortization419,914326,9831,259,742512,100
Impairment of goodwill2,520,382–3,207,227 
Total Expenses(6,734,688)(6,263,021)(15,987,728)(15,098,188)
Other income (loss)378,51272,748(2,117,968)473,646
Net loss before taxes(7,667,152)(6,185,330)(17,422,870)(14,579,005)
Net loss after taxes(7,667,152)(6,185,330)(17,422,870)(14,579,005)
Weighted average number of Common Shares outstanding – basic and diluted26,566,91521,830,15325,348,33019,298,899
Loss per share – basic and diluted(0.35)(0.33)(0.82)(0.84)

Summary of Balance Sheet ($CDN)

  As at September 30, 2020As at December 31, 2019
    
Assets $$
Cash 101,088441,757
Amounts receivable 2,442,4881,202,924
Prepaid assets 652,287704,632
Biological assets 233,644117,367
Inventory 2,084,4141,484,371
Right to use asset 392,516539,710
Property and equipment 19,951,26522,622,322
Intangible assets 10,504,18211,063,900
Derivative asset 1,501,0343,780,000
Investments 7272
Goodwill –3,207,227
Total Assets 37,862,99045,164,282
Liabilities and Equity   
Amounts payable 4,815,1325,177,634
Due to related party 4,952,1243,319,116
Convertible debentures 757,400715,626
Derivative liability –23,434
Lease liability 417,975555,339
Term loan ––
Deferred revenue 3,074,7523,323,518
Deferred tax liability 2,173,8342,173,834
Total Liabilities 16,191,21715,288,501
Shareholder’s equity 21,671,77329,875,781
Total Liabilities and Shareholder’s Equity 37,862,99045,164,282

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

  • Pura H&W: an advanced and clinically tested line of CBD consumer dermacosmetic products; and,
  • RHO Phyto: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its dermacosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation (each such statement a “forward-looking statement”).  Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Avicanna’s current beliefs and assumptions regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Avicanna’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include,  the Company’s revenues to continue to increase through fiscal 2021, the Company’s anticipated activities and results of its various commercial initiatives, its availability and sufficiency of working capital, the anticipated growth of the Company’s business in the first quarter of 2021 and the anticipated further development and improvement of products by the Company.

By identifying such information and statements in this manner, Avicanna is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avicanna to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking statements contained in this press release, Avicanna has made certain assumptions.

Among others, the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: decreases in the prevailing prices for cannabis and cannabis products in the markets in which the Company operates; adverse changes in applicable laws; adverse changes in the application or enforcement of current laws, including those related to taxation; increasing costs of compliance with extensive government regulation; changes in general economic, business and political conditions, including changes in the financial markets ; risks related to licensing, including the ability to obtain the requisite licenses or renew existing licenses for the Company’s existing and proposed operations; dependence upon third party service providers, skilled labor and other key inputs; risks inherent in the agricultural and retail business; intellectual property risks; risks related to litigation; dependence upon senior management; and the other risks disclosed in the Company’s long form final prospectus dated July 8, 2019 and the Company’s annual information form dated April 15, 2020. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Avicanna believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking statements are reasonable, undue reliance should not be placed on such statements, and no assurance or guarantee can be given that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Tags: , , , , , , , , , ,
Posted in All Recent Posts, Avicanna Inc. | Comments Off on Avicanna $AVCN.ca $AVCNF Reports Third Quarter 2020 Financial Results and Provides Corporate Update $WEED.ca $TLRY $HARV.ca

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:14 AM on Thursday, November 12th, 2020
kontrol-logo

Kontrol BioCloud a Safe Space Technology™

  • Received UL standards approval for its BioCloud® technology
  • As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.
  • “We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

TORONTO, ON / November 12, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has received UL standards approval for its BioCloud® technology. As referenced in the press release dated November 5th, 2020, Kontrol has previously received CSA standards approval and has now received UL standards approval.

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

Field Certification was provided by ESAFE

Underwriters’ Laboratories or UL regulations require manufacturers of products sold in the United States to receive UL Standards approval for electrical safety.

ESAFE is accredited by the Standards Council of Canada (SCC), as an Inspection Body (ISO 17020) and Certification Body (ISO 17065). As an accredited agency, ESAFE is authorized to approve and label equipment for electrical safety.

www.esafe.org

About Kontrol BioCloud®

BioCloud® is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud® has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others

BioCloud® is not a medical device and the Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud®) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Tags: , , , , , , , , , , ,
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol $KNR $KNR.ca $KNR.c $KNRLF Receives UL Standards Approval for BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Peak $PKK.ca $PKKFF Records First Transactions Related to Program Bringing Financing to 60K Online Stores $ALY.ca $DELX.ca $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

Posted by AGORACOM-JC at 7:39 AM on Thursday, November 12th, 2020
Peak Fintech Group (@PEAK_Fintech) | Twitter
  • Announced that its Cubeler Lending Hub commercial lending platform has facilitated the first transactions related to a program created by the Company and consumer electronics wholesale distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients
  • Newly-created purchase order financing program allows BDC’s clients, who collectively sell about CAD$50B worth of consumer electronics per year, to have up to 90% of the price of the products they purchase financed by any bank or lending institution represented on the Lending Hub.
  • Purchase orders for iPhones totalling a combined 48M RMB (about CAD$9.5M) coming from four JD.com (www.jd.com) affiliated stores were the first orders approved for funding through the program

\Montreal, Quebec–(November 12, 2020) – Peak Positioning Technologies Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that its Cubeler Lending Hub commercial lending platform has facilitated the first transactions related to a program created by the Company and consumer electronics wholesale distributor Beijing Dianjing Company Ltd. (“BDC”) to bring financing solutions to BDC’s 60,000 online retail clients.

The newly-created purchase order financing program allows BDC’s clients, who collectively sell about CAD$50B worth of consumer electronics per year, to have up to 90% of the price of the products they purchase financed by any bank or lending institution represented on the Lending Hub.

Purchase orders for iPhones totalling a combined 48M RMB (about CAD$9.5M) coming from four JD.com (www.jd.com) affiliated stores were the first orders approved for funding through the program. The platform collected a fee equivalent to 2% of the annualized interest rate charged by the lender to finance the orders. The financing program was expected to start in early December, but pressing demand from the stores led Peak and BDC to take special measures to allow for these first transactions to be processed while the program is still undergoing minor adjustments.

“Our market research showed that there would be strong demand from online retailers for Lending Hub’s services, but we weren’t expecting to have to start the program almost a full month ahead of schedule,” commented Peak Group China CEO, Mr. Liang Qiu. “Retailers continuously buy and sell inventory and thus have an ongoing need for credit, a need that wasn’t properly addressed until today. We created a program that uses AI and analytics to help retailers buy more products from wholesalers, and are working with some of the country’s largest wholesale distributors to expand it nationwide. I think we have a unique opportunity here to positively impact a large segment of China’s CAD$6.5 trillion annual retail market. This is yet another way in which we believe we can accelerate the proliferation of the Lending Hub to every part of the country.”

About Peak Positioning Technologies Inc.:

Peak Positioning Technologies Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://peakfintechgroup.com/.

For more information, please contact:

CHF Capital Markets
Cathy Hume, CEO
416-868-1079 ext.: 251
[email protected]

Peak Positioning Technologies Inc.
Johnson Joseph, President and CEO
514-340-7775 ext.: 501
[email protected]

Twitter: @peakfintech
Facebook: @peakfintech
LinkedIn: Peak Positioning
YouTube: Peak Positioning

Forward-Looking Statements / Information:

This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.

Tags: , , , , , , , , , , , , ,
Posted in All Recent Posts, Featured, Peak Fintech Group, Peak Positioning Technologies Inc. | Comments Off on Peak $PKK.ca $PKKFF Records First Transactions Related to Program Bringing Financing to 60K Online Stores $ALY.ca $DELX.ca $MOS.ca $MOGO.ca CTZ.ca $TRAD.ca

TransCanna $TCAN.ca Announces Five Year Deal with Fresca LLC $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Posted by AGORACOM-JC at 7:26 AM on Thursday, November 12th, 2020
tcan-square
  • Lyfted Farms has entered into a 5-year agreement with Fresca LLC to promote and co-brand premium indoor cannabis flower
  • The resulting new retail SKU’s have surpassed several prior sales velocity records for Lyfted Farms
  • Sales velocity has long been a key indicator for demand and viable results demonstrating the products are well positioned

Vancouver, British Columbia–(November 12, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (GSE: TH8) (“TransCanna” or the “Company”) announces the collaboration of Lyfted Farms with Fresca LLC; breaks sales velocity records.

Lyfted Farms has entered into a 5-year agreement with Fresca LLC to promote and co-brand premium indoor cannabis flower. The resulting new retail SKU’s have surpassed several prior sales velocity records for Lyfted Farms. Sales velocity has long been a key indicator for demand and viable results demonstrating the products are well positioned.

This collaboration highlights the marketplace power of California’s most authentic indoor cultivator combined with the Fresca Brand and distribution channels into the world-famous Cookie’s, Lemonade, and Dr. Greenthumb stores.

Bob Blink, founder of Lyfted Farms and CEO of TransCanna, shares that, “The opportunity to bring Lyfted Farms reputation for consistently high quality indoor cannabis flower into the Fresca Brand and the Cookie’s retail distribution system is exciting and will enable us to showcase the production capacity of the Daly Facility.”

Gilbert Milam Jr., aka “Berner” @berner415, Founder and CEO of Cookie’s, notes “The owners of Fresca helped innovate Bay Area culture when I was growing up through music…when they mentioned to me about starting a cannabis brand…I recommended that they find a quality indoor cultivator and I think Lyfted Farms is the perfect partner for them. We look forward to carrying their brand onto our shelves and watching their Statewide expansion.”

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed, Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

Tags: , , , , , , , , ,
Posted in All Recent Posts, Featured, TransCanna Holdings Inc. | Comments Off on TransCanna $TCAN.ca Announces Five Year Deal with Fresca LLC $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

« Older Entries
Newer Entries »